NASDAQ:MLTX MoonLake Immunotherapeutics Q4 2024 Earnings Report $15.62 +0.06 (+0.39%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast MoonLake Immunotherapeutics EPS ResultsActual EPS-$0.72Consensus EPS -$0.63Beat/MissMissed by -$0.09One Year Ago EPSN/AMoonLake Immunotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoonLake Immunotherapeutics Announcement DetailsQuarterQ4 2024Date2/26/2025TimeBefore Market OpensConference Call DateWednesday, February 26, 2025Conference Call Time9:30AM ETUpcoming EarningsMoonLake Immunotherapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(10-K) MoonLake Immunotherapeutics Earnings HeadlinesMoonLake Immunotherapeutics (MLTX)August 23 at 10:09 PM | finance.yahoo.comWhat is HC Wainwright's Forecast for MLTX Q3 Earnings?August 17, 2026 | americanbankingnews.comBuffett’s “Green New Deal” (trigger warning!)Warren Buffett's largest stock bet ever now tops 29 billion dollars, dwarfing his historic positions in Coca-Cola and Apple. He built the stake in a company progressives have long targeted for elimination, and regulators have cleared him to own up to 50 percent of shares outstanding. Analysts wonder if Buffett could eventually bid for the entire company.August 26 at 1:00 AM | Porter & Company (Ad)MoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’August 11, 2026 | msn.comMoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical GoalsAugust 10, 2026 | finance.yahoo.comMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...August 10, 2026 | markets.businessinsider.comSee More MoonLake Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email. Email Address About MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.View MoonLake Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-RaisePhotronics Is Quietly Becoming a Key Winner From the AI BoomOpenAI’s Jalapeño Chip Could Change the AI Hardware RaceHONA: The Spin-Off Story the Market Is Reading WrongPDD Beat Earnings—So Why Did the Stock Still Fall?Marzetti Stock Confirms Reversal on Earnings Strength, Dividend GrowthDICK's Sporting Goods Faces Pain Now for a Bigger Prize Upcoming Earnings Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
